PAPPA2 and non-small cell lung carcinoma: Secondly, interestingly enough, in the TCGA database, we did not find the PFS/OS difference between PAPPA2‐Mut and PAPPA2‐WT neither in LUAD, LUSC, NSCLC or SKCM, suggesting it was not a prognosis biomarker, contrary to its role in Ayako Suzuki cohort (7/90, about 7.7%) as a prognosis biomarker.25